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EFFECTS OF METFORMIN ON SPONTANEOUS AND CLOMIPHENE-INDUCED 
OVULATION IN THE POLYCYSTIC OVARY SYNDROME
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BSTRACT
 
Background
 
Obese women with the polycystic
ovary syndrome are relatively unresponsive to the
induction of ovulation by clomiphene. We hypothe-
sized that reducing insulin secretion by administer-
ing metformin would increase the ovulatory re-
sponse to clomiphene.
 
Methods
 
We performed oral glucose-tolerance
tests before and after the administration of 500 mg
of metformin or placebo three times daily for 35
days in 61 obese women with the polycystic ovary
syndrome. Women who did not ovulate spontane-
ously were then given 50 mg of clomiphene daily for
five days while continuing to take metformin or pla-
cebo. Serum progesterone was measured on days
14, 28, 35, 44, and 53, and ovulation was presumed
to have occurred if the concentration exceeded 8 ng
per milliliter (26 nmol per liter) on any of these days.
 
Results
 
Twenty-one women in the metformin
group and 25 women in the placebo group were giv-
en clomiphene because they did not ovulate sponta-
neously during the first phase of the study. Among
the 21 women given metformin plus clomiphene,
the mean (±SE) area under the serum insulin curve
after oral glucose administration decreased from
6745±2021 to 3479±455 µU per milliliter per minute
(40.5±12.1 to 20.9±2.7 nmol per liter per minute,
P=0.03), but it did not change significantly in the 25
women given placebo plus clomiphene. Nineteen of
the 21 women (90 percent) who received metformin
plus clomiphene ovulated (mean peak serum pro-
gesterone concentration, 23.8±3.4 ng per milliliter
[7.6±10.9 nmol per liter]). Two of the 25 women
(8 percent) who received placebo plus clomiphene
ovulated (P<0.001). Overall, 31 of the 35 women (89
percent) treated with metformin ovulated spontane-
ously or in response to clomiphene, as compared with
3 of the 26 women (12 percent) treated with placebo.
 
Conclusions
 
The ovulatory response to clomiphene
can be increased in obese women with the polycys-
tic ovary syndrome by decreasing insulin secretion
with metformin. (N Engl J Med 1998;338:1876-80.)
 
©1998, Massachusetts Medical Society.
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lottesville (W.S.E.); and the University of Bologna, Bologna, Italy (R.P.).
Address reprint requests to Dr. Nestler at the Medical College of Virginia,
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OLYCYSTIC ovary syndrome, which affects
approximately 6 percent of women of repro-
ductive age and is characterized by chronic
anovulation and hyperandrogenism,
 
1
 
 is the
most common cause of infertility in women in the
United States. Insulin resistance with compensatory
hyperinsulinemia is a prominent feature of the syn-
P
 
drome
 
2-5
 
 and appears to have a pathophysiologic
role in the hyperandrogenism of the disorder. Ovar-
ian androgen production and serum free testoster-
one concentrations decrease in women with polycys-
tic ovary syndrome when insulin secretion is reduced
by drugs such as diazoxide,
 
6
 
 metformin,
 
7-10 
 
and tro-
glitazone.
 
11,12
 
 However, whether such therapy im-
proves ovulatory function is not known.
Clomiphene citrate, an antiestrogenic drug, is the
primary therapy used for ovulation induction in
women with the polycystic ovary syndrome.
 
13-15
 
However, obese women with the syndrome often re-
quire multiple courses and high doses of clomi-
phene, and there is a positive correlation between
obesity and the dose of clomiphene required to in-
duce ovulation.
 
15
 
 Since increasing obesity is associ-
ated with increasing hyperinsulinemia,
 
16
 
 the high de-
gree of hyperinsulinemia in obese women with the
polycystic ovary syndrome may account for their
poor responsiveness to clomiphene.
 
13
 
 Hyperinsuline-
mia could adversely affect folliculogenesis and ovu-
lation by increasing intraovarian androgen produc-
tion,
 
6,8,17-19
 
 altering gonadotropin secretion,
 
8,9,20-22
 
 or
directly affecting follicular development.
The aim of this study was to determine whether
reducing hyperinsulinemia with metformin would in-
crease the ovulatory response to clomiphene in obese
women with the polycystic ovary syndrome.
 
METHODS
 
Subjects
 
We studied 61 obese women (body-mass index [the weight in
kilograms divided by the square of the height in meters], >28)
with polycystic ovary syndrome in the United States, Venezuela,
and Italy. All had oligomenorrhea (fewer than six menstrual pe-
riods in the preceding year) and hyperandrogenemia (elevated se-
rum free testosterone concentrations, determined at local clinics),
and none had diabetes mellitus. All had normal serum prolactin
concentrations and normal thyroid-function tests. Late-onset
adrenal hyperplasia was ruled out by the finding of a morning se-
rum 17
 
a
 
-hydroxyprogesterone concentration below 200 ng per
deciliter (6 nmol per liter). All the women had findings on ultra-
sonography of the ovaries consistent with the diagnosis of the
polycystic ovary syndrome.
 
23
 
 Thirty-one women had received clo-
miphene previously, but none had taken it or any other medica-
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tion for at least two months before the study. The study was ap-
proved by the institutional review board at each study site, and
each woman gave informed consent.
 
Experimental Protocol
 
At the time of entry into the study, all the women were in the
equivalent of the follicular phase of the menstrual cycle, as docu-
mented by a serum progesterone concentration below 2 ng per
milliliter (6.4 nmol per liter), and their last episode of menstrual
bleeding had been at least two months earlier.
On day 0, the women came to the hospital after a 12-hour
overnight fast, at which time their weight, height, and waist-
to-hip ratio were measured. Blood samples were drawn at 8:30,
8:45, and 9 a.m., and equal volumes of serum were pooled for
the measurement of insulin, glucose, steroid hormones, and sex
hormone–binding globulin. At 9 a.m. 75 g of glucose was given
orally, and blood samples were collected after 60 and 120 min-
utes for the determination of serum glucose and insulin concen-
trations.
Findings from a previous study
 
8
 
 suggested that metformin
might increase spontaneous ovulation. Given that a goal of the
study was to have an equal number of women in the metformin
and placebo groups during the administration of clomiphene,
more women were randomly assigned to receive metformin. Thir-
ty-five women were assigned to take 500 mg of metformin (Glu-
cophage, Bristol-Myers Squibb, Princeton, N.J.; Glafornil, North
Medicamenta, Caracas, Venezuela; or Metforal, Laboratori Gui-
dotti, Pisa, Italy) orally three times daily, and the remaining 26
women were assigned to receive placebo. The women were asked
to abstain from sexual intercourse or to use a barrier method of
contraception during the study.
The women took metformin or placebo alone on days 1 to 34
to allow sufficient time for metformin to exert its putative insulin-
sensitizing effects. Serum progesterone was measured on days 14,
28, and 35, and ovulation was presumed to have occurred if the
value exceeded 8 ng per milliliter (25.6 nmol per liter) on any of
these days. All tests performed at base line (day 0) were repeated
on day 35.
The 21 women in the metformin group and the 25 women in
the placebo group who did not ovulate and had serum progester-
one concentrations below 2 ng per milliliter between days 0 and
35 were given 50 mg of clomiphene citrate (Serophene, Teva
Pharmaceuticals, Jerusalem, Israel) daily for five days (days 35 to
39), while continuing to receive metformin or placebo through
day 53. Serum progesterone was measured on days 44 and 53 to
assess the ovulatory response to clomiphene.
 
Assays
 
Blood samples were centrifuged as soon as they were obtained,
and the serum was stored at ¡20°C until assayed. Serum hor-
mones and sex hormone–binding globulin (measured as protein)
were assayed as previously described,
 
6,24,25
 
 except for serum free
testosterone, the concentration of which was calculated according
to the method of Sodergard et al.
 
26
 
 and was predicated on the
assumption of a constant serum albumin concentration of 4.0 g
per deciliter. To avoid variation between assays, all samples from
an individual woman were analyzed in duplicate in a single assay
for each hormone. The intraassay coefficient of variation was 5.5
percent for the insulin assay and less than 10 percent for all ster-
oid hormone assays.
 
Statistical Analysis
 
We analyzed the serum glucose and insulin responses to oral
glucose administration by calculating the areas under the re-
sponse curves by the trapezoidal rule using absolute values. Fish-
er’s exact test was used to analyze the differences in ovulation
rates between the metformin and placebo groups. For other var-
iables, we compared results within a group by testing for normal-
ity with the Wilk–Shapiro test and then using Student’s two-
tailed paired t-test or the Wilcoxon signed-rank test, and we com-
pared results between groups with Student’s two-tailed unpaired
t-test or the Mann–Whitney rank-sum test.
 
RESULTS
 
Treatment with Metformin or Placebo Alone
 
On entry into the study (day 0), the metformin
and placebo groups did not differ with respect to
history of clomiphene treatment, anthropometric
variables, and biochemical values (Table 1).
In the metformin group, the mean (±SE) area
under the serum insulin curve during the oral glu-
cose-tolerance test decreased from 6598±1267 to
3764±317 µU per milliliter per minute (39.6±7.6
to 22.6±1.9 nmol per liter per minute, P=0.002),
whereas this value did not change significantly in the
placebo group (P=0.20). There was also a small but
significant decrease in the waist-to-hip ratio during
testing (from 0.89±0.01 to 0.88±0.01, P<0.001)
in the metformin group, but not in the placebo
group (P=0.60). In neither group was there any
 
*Plus–minus values are means ±SE. To convert values for insulin to pi-
comoles per liter, multiply by 6.0; to convert values for glucose to milli-
moles per liter, multiply by 0.056; to convert values for progesterone to
nanomoles per liter, multiply by 3.2; to convert values for testosterone to
picomoles per liter, multiply by 34.7; to convert values for androstenedione
to picomoles per liter, multiply by 34.9; to convert values for 17
 
b
 
-estradiol
to picomoles per liter, multiply by 3.67; to convert values for dehydroepi-
androsterone sulfate to micromoles per liter, multiply by 0.027; and to con-
vert values for sex hormone–binding globulin to nanomoles per liter, mul-
tiply by 34.7.
†The area under the curve (AUC) of the responses of serum glucose and
insulin to oral glucose administration was calculated.
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C
 
HARACTERISTIC
 
M
 
ETFORMIN
 
G
 
ROUP
 
(N=35)
P
 
LACEBO
 
G
 
ROUP
 
(N=26)
 
Age — yr 29±1 28±1
Previous treatment with clomiphene
— no. (%)
18 (51) 13 (50)
Body-mass index 32.3±0.8 32.2±1.0
Waist-to-hip ratio 0.89±0.01 0.90±0.01
Serum insulin during fasting
— µU/ml
19±2 22±6
Serum glucose during fasting
— mg/dl
78±3 75±2
AUC
 
insulin
 
 — µU/ml/min† 6598±1267 6558±1030
AUC
 
glucose
 
 — mg/dl/min† 11,277±553 10,914±486
Serum progesterone — ng/ml 0.8±0.1 0.6±0.1
Serum testosterone — ng/dl 70±5 63±5
Serum free testosterone — ng/dl 1.0±0.1 0.8±0.1
Serum androstenedione — ng/dl 232±13 215±18
Serum 17
 
b
 
-estradiol — pg/ml 47±6 56±10
Serum dehydroepiandrosterone
sulfate — µg/dl
222±23 211±21
Serum sex hormone–binding
globulin — µg/dl
2.0±0.2 2.7±0.4
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change in the body-mass index, serum insulin or
glucose concentrations during fasting, or the area
under the serum glucose curve during the oral glu-
cose-tolerance test.
During the first 35 days of treatment, serum total
testosterone concentrations did not change signifi-
cantly in either the metformin group (P=0.84) or
the placebo group (P=0.53). Serum sex hormone–
binding globulin concentrations increased in both
the metformin group (from 2.0±0.2 to 2.7±0.3 µg
per deciliter [69±7 to 93±10 nmol per liter], P=
0.01) and the placebo group (2.7±0.4 to 3.6±0.5
µg per deciliter [94±13 to 124±17 nmol per liter],
P=0.06). As a result, serum free testosterone con-
centrations decreased in the metformin group, from
1.0±0.1 to 0.8±0.1 ng per deciliter (347±35 to
278±35 pmol per liter, P=0.07), and in the placebo
group, from 0.8±0.1 to 0.6±0.1 ng per deciliter
(278±35 to 208±35 pmol per liter, P=0.04).
Twelve of the 35 women (34 percent) in the met-
formin group ovulated spontaneously during treat-
ment with metformin alone, as compared with only
1 of the 26 women (4 percent) in the placebo group
(P<0.001). The mean peak serum progesterone
concentration in the 12 women in the metformin
group who ovulated was 13.0±1.0 ng per milliliter
(41.6±3.2 nmol per liter). Two other women in the
metformin group had peak serum progesterone con-
centrations between 4 and 8 ng per milliliter (12.8
to 25.6 nmol per liter) and were not included in the
second phase of the study. Figure 1 shows the num-
ber of women who had serum progesterone concen-
trations above 8 ng per milliliter (indicative of ovu-
lation) on days 14, 28, and 35 in the metformin and
placebo groups.
 
Treatment with Clomiphene and Metformin or Placebo
 
Twenty-one women in the metformin group and
25 women in the placebo group continued into the
second phase of the study, during which they received
concurrent clomiphene treatment. The two groups
had not differed on study day 0 with respect to the
area under the serum insulin curve (6745±2021 µU
per milliliter per minute [40.5±12.1 nmol per liter
per minute] in the group given metformin and clo-
miphene, as compared with 6574±1072 µU per mil-
liliter per minute [39.4±6.4 nmol per liter per min-
ute] in the group given placebo and clomiphene;
P=0.83), but on day 35, before clomiphene treat-
ment was started, this value was significantly lower in
the group given metformin and clomiphene (P=0.03)
(Table 2). The difference was due to a 48 percent de-
crease (P=0.03) in the value in the 21 women in the
group given metformin and clomiphene between
days 0 and 35, from 6745±2021 to 3479±455 µU
per milliliter per minute (40.5±12.1 to 20.9±2.7
 
Figure 1.
 
 Number of Women with a Serum Progesterone Concentration above 8 ng per Milliliter on
Each Day of the Study on Which It Was Measured.
During days 1 to 34 the women were treated with metformin or placebo alone. On day 35, ovulation
induction with clomiphene was started while metformin or placebo was continued. Only women
whose serum progesterone concentrations were less than 2 ng per milliliter throughout the first phase
of the study were included in the ovulation-induction phase of the study.
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nmol per liter per minute). On day 35 the two groups
did not differ with respect to history of clomiphene
treatment, anthropometric variables, or biochemical
values (Table 2).
Nineteen of the 21 women (90 percent) who re-
ceived combined metformin and clomiphene ovulat-
ed; the mean peak serum progesterone concentra-
tion in these 19 women was 23.8±3.4 ng per
milliliter (76.1±10.9 nmol per liter). In contrast,
only 2 of the 25 women (8 percent) in the group
given placebo and clomiphene ovulated (P<0.001);
2 other women in this group had serum progester-
one concentrations between 4 and 8 ng per millili-
ter. Figure 1 shows the number of women who had
serum progesterone concentrations above 8 ng per
milliliter on days 44 and 53 in the two groups.
 
DISCUSSION
 
We conducted this study to determine whether
decreasing insulin secretion in obese women with
the polycystic ovary syndrome would facilitate the
induction of ovulation by clomiphene. We found
that treatment with metformin, but not placebo, sig-
nificantly decreased the serum insulin response to
oral glucose administration. Simultaneously with
the reduction in serum insulin, the women given
metformin had marked increases in both spontane-
ous ovulation and clomiphene-induced ovulation, as
compared with the women given placebo. Thirty-
one of the 35 women treated with metformin (89
percent) ovulated either spontaneously or in re-
sponse to clomiphene, as compared with only 3 of
the 26 women in the placebo group (12 percent).
These findings support the idea that hyperinsuline-
mia impedes ovulation in obese women with the
polycystic ovary syndrome and that decreasing insu-
lin secretion facilitates both spontaneous ovulation
and the induction of ovulation by clomiphene.
Our findings are consistent with those of previous
studies that noted an increased frequency of men-
struation or ovulation in women with the polycystic
ovary syndrome during treatment with metformin
 
7-9
 
or troglitazone.
 
11,12
 
 However, the specific effect of
insulin reduction on ovulation was not assessed in
those studies. In a recent study, several previously
infertile women with the polycystic ovary syndrome
who were treated with metformin for six months be-
came pregnant.
 
27
 
 However, the study was uncon-
trolled and was not specifically designed to monitor
ovulation, and nearly half the women recruited did
not complete the study. None of the studies exam-
ined the effect of the reduction in insulin secretion
on the induction of ovulation by clomiphene.
 
7-9,11,12,27
 
To assess clomiphene-induced ovulation, we pur-
posefully chose to administer a low daily dose of
only 50 mg of clomiphene, because few obese wom-
en with the polycystic ovary syndrome would be ex-
pected to have a response to this dose.
 
13,15
 
 For exam-
ple, in a study of women with the polycystic ovary
syndrome who weighed more than 91 kg (200 lb),
50 mg of clomiphene daily for five days resulted in
an ovulatory rate of only 20 percent.
 
15
 
 The rate of
clomiphene-induced ovulation was lower in our pla-
cebo group, most likely because half the women had
not had a response to previous clomiphene therapy.
We chose to use metformin because several previ-
ous studies had documented its ability to decrease
serum insulin in women with the polycystic ovary
syndrome.
 
7-10,28
 
 It is classified as a category B drug,
which means that no teratogenic effects have been
demonstrated in vitro. It is commonly given to pre-
menopausal women with type II diabetes mellitus
and simply discontinued when they become preg-
nant. Metformin was administered to a limited num-
ber of South African women with diabetes through-
out their pregnancies,
 
28
 
 and no teratogenic effects
 
*Plus–minus values are means ±SE. To convert values for insulin to pi-
comoles per liter, multiply by 6.0; to convert values for glucose to milli-
moles per liter, multiply by 0.056; to convert values for progesterone to
nanomoles per liter, multiply by 3.2; to convert values for testosterone to
picomoles per liter, multiply by 34.7; to convert values for androstenedione
to picomoles per liter, multiply by 34.9; to convert values for 17
 
b
 
-estradiol
to picomoles per liter, multiply by 3.67; to convert values for dehydroepi-
androsterone sulfate to micromoles per liter, multiply by 0.027; and to con-
vert values for sex hormone–binding globulin to nanomoles per liter, mul-
tiply by 34.7.
†The area under the curve (AUC) of the responses of serum glucose and
insulin to oral glucose administration was calculated.
‡P=0.03 for the comparison with the group given placebo plus clomi-
phene.
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FOR
 
 35 D
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.*
 
C
 
HARACTERISTIC
 
M
 
ETFORMIN
 
 
 
PLUS
 
C
 
LOMIPHENE
 
(N=21)
P
 
LACEBO
 
 
 
PLUS
 
C
 
LOMIPHENE
 
(N=25)
 
Age — yr 30±1 28±1
Previous treatment with clomiphene
— no. (%)
11 (52) 13 (52)
Body-mass index 34.0±1.0 32.2±1.1
Waist-to-hip ratio 0.88±0.01 0.90±0.01
Serum insulin during fasting
— µU/ml
14±2 13±3
Serum glucose during fasting
— mg/dl
81±3 76±2
AUC
 
insulin
 
 — µU/ml/min† 3479±455‡ 5100±55
AUC
 
glucose
 
 — mg/dl/min† 11,089±587 10,839±500
Serum progesterone — ng/ml 0.8±0.1 0.6±0.1
Serum testosterone — ng/dl 66±5 59±6
Serum free testosterone — ng/dl 0.8±0.1 0.6±0.1
Serum androstenedione — ng/dl 210±18 200±20
Serum 17
 
b
 
-estradiol — pg/ml 68±13 54±9
Serum dehydroepiandrosterone
sulfate — µg/dl
201±20 155±14
Serum sex hormone–binding
globulin — µg/dl
2.7±0.4 3.6±0.5
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were reported. It is not known to influence hypotha-
lamic, pituitary, or ovarian function independently,
but this possibility cannot be ruled out.
There are two main limitations to our study. First,
pregnancy was not an outcome measure, and we do
not know whether the increased frequency of ovula-
tion would be accompanied by an increased preg-
nancy rate or birth rate. Second, we do not know
whether the improved ovulatory function in the
women given metformin was due to a decrease in in-
traovarian androgen production, normalization of
spontaneous or clomiphene-induced gonadotropin
secretion, diminution of the potential direct effects
of insulin on ovarian folliculogenesis, or a combina-
tion of these processes.
In summary, the frequency of spontaneous ovula-
tion and ovulation induced by clomiphene can be
increased in obese women with the polycystic ovary
syndrome by decreasing serum insulin concentra-
tions with metformin.
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